^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Commun (Lond)
    Title:

    KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

    Published date:
    07/11/2022
    Excerpt:
    A clinical cohort of 74 NSCLC patients that harbored KRAS mutations and received anti-PD-1/PD-L1 monotherapy…the NSCLC patients with KRAS-G12D mutations had significantly shorter progression-free survival (PFS) than those with other point mutations (P = 0.006; Figure 1B).
    DOI:
    https://doi.org/10.1002/cac2.12327